Valuation : Intervacc AB

Market Cap 37Cr 3.85Cr 3.31Cr 3.1Cr 2.84Cr 5.34Cr 368.04Cr 5.36Cr 14Cr 185.49Cr 14Cr 14Cr 613.89Cr P/E 2026 *
-0.96x
P/E 2027 * -0.96x
Enterprise Value 28Cr 2.92Cr 2.51Cr 2.35Cr 2.15Cr 4.05Cr 278.72Cr 4.06Cr 11Cr 140.47Cr 11Cr 11Cr 464.91Cr EV / Sales 2026 *
13.2x
EV / Sales 2027 * 10.2x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day-0.56%
1 week-4.12%
Current month-15.75%
1 month-15.75%
3 months-12.30%
6 months+72.30%
Current year+15.80%
1 week 1
Extreme 0.999
1.2
1 month 1
Extreme 0.999
1.35
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
76.5
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 05/02/2026
Director of Finance/CFO - 06/02/2020
Chief Tech/Sci/R&D Officer - 11/06/2020
Director TitleAgeSince
Chairman 56 13/05/2026
Director/Board Member 72 01/01/2024
Director/Board Member 68 01/01/2025
Date Insider Type Main position Quantity % Market Cap.
23/02/25 Free

Chief Financial Officer

9,29,208 1.2269%
17/02/25 Buy

Chief Executive Officer

1,35,000 0.1783%
17/02/25 Sell

Chief Executive Officer

2,78,820 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%-4.12%+7.00%-74.46% 3.85Cr
+3.31%-3.70%+61.03%+103.64% 7.04TCr
+1.09%+2.51%+49.34%+93.23% 6.54TCr
-0.88%+0.32%+7.99%-7.82% 2.83TCr
-0.49%+5.43%+54.81%+13.87% 2.66TCr
-1.59%-2.28%-9.14%+465.36% 2.72TCr
+0.37%+1.21%+36.55%-17.60% 2.01TCr
+1.02%+6.43%+269.42%+420.34% 2.06TCr
+0.77%+0.19%+8.01%+520.34% 1.59TCr
-1.68%+2.78%+43.29%+148.78% 1.39TCr
Average +0.14%+0.68%+52.83%+166.57% 2.88TCr
Weighted average by Cap. +0.84%+0.72%+55.40%+155.43%

Financials

2026 *2027 *
Net sales 2.11Cr 22.17L 19.03L 17.82L 16.32L 30.74L 21Cr 30.82L 82.48L 11Cr 83.25L 81.45L 35Cr 3Cr 31.58L 27.11L 25.38L 23.24L 43.77L 30Cr 43.9L 1.17Cr 15Cr 1.19Cr 1.16Cr 50Cr
Net income -8.24Cr -86.64L -74.37L -69.63L -63.76L -1.2Cr -83Cr -1.2Cr -3.22Cr -42Cr -3.25Cr -3.18Cr -138.02Cr -8.36Cr -87.9L -75.45L -70.64L -64.69L -1.22Cr -84Cr -1.22Cr -3.27Cr -42Cr -3.3Cr -3.23Cr -140.03Cr
Net Debt -8.9Cr -93.52L -80.28L -75.16L -68.82L -1.3Cr -89Cr -1.3Cr -3.48Cr -45Cr -3.51Cr -3.44Cr -148.99Cr -6.1Cr -64.1L -55.02L -51.51L -47.17L -88.86L -61Cr -89.11L -2.38Cr -31Cr -2.41Cr -2.35Cr -102.12Cr
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
27/26/27 SEK 1.070 -0.56% 4,17,515
26/26/26 SEK 1.076 -1.82% 1,42,876
25/26/25 SEK 1.096 -2.84% 1,90,375
24/26/24 SEK 1.128 +3.87% 1,54,899
21/26/21 SEK 1.086 -1.63% 5,10,315

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock